Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma

R R H van den Brom, Suzanne Es, van, A. M. Leliveld, J.A. Gietema, Geke A.P. Hospers, Igle Jan Jong, de, E G E de Vries, S. F. Oosting*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)
281 Downloads (Pure)

Abstract

The number of elderly patients with renal cell carcinoma is rising. Elderly patients differ from their younger counterparts in, among others, higher incidence of comorbidity and reduced organ function. Age influences outcome of surgery, and therefore has to be taken into account in elderly patients eligible for cytoreductive nephrectomy. Over the last decade several novel effective drugs have become available for the metastatic setting targeting angiogenesis and mammalian target of rapamycin. Immune checkpoint blockade with a programmed death 1 antibody has recently been shown to increase survival and further studies with immune checkpoint inhibitors are ongoing. In this review we summarize the available data on efficacy and toxicity of existing and emerging therapies for metastatic renal cell carcinoma in the elderly. Where possible, we provide evidence-based recommendations for treatment choices in elderly. (C) 2016 The Authors. Published by Elsevier Ltd.

Original languageEnglish
Pages (from-to)63-72
Number of pages10
JournalCANCER TREATMENT REVIEWS
Volume46
DOIs
Publication statusPublished - May-2016

Keywords

  • Renal cell carcinoma
  • Elderly
  • Nephrectomy
  • Angiogenesis inhibitors
  • Mammalian target of rapamycin inhibitors
  • Programmed death 1
  • Immunotherapy
  • PHASE-III TRIAL
  • EXPANDED ACCESS PROGRAM
  • CANCER-TREATMENT TRIALS
  • INTERFERON-ALPHA
  • CYTOREDUCTIVE NEPHRECTOMY
  • CLINICAL-TRIALS
  • OLDER PATIENTS
  • RADICAL NEPHRECTOMY
  • RANDOMIZED-TRIAL
  • DOUBLE-BLIND

Cite this